Association Between Hormone Levels and Retinopathy in Patients With Type 2 Diabetes: A Cross-Sectional Study.

Yu Meng, Xueli Yang, Yuxin Fan, Ming Liu, Fengqi Zhou, Qihua Wang, Yuezhu Lu, Yun Zhu, Hua Yan
Author Information
  1. Yu Meng: Department of Ophthalmology, Tianjin Medical University General Hospital Airport Hospital, Tianjin, China.
  2. Xueli Yang: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
  3. Yuxin Fan: Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, China.
  4. Ming Liu: Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, China.
  5. Fengqi Zhou: Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
  6. Qihua Wang: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
  7. Yuezhu Lu: Department of Ophthalmology, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
  8. Yun Zhu: Department of Epidemiology & Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, China.
  9. Hua Yan: Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.

Abstract

Purpose: To explore the relationship between hormone levels and diabetic Retinopathy (DR).
Methods: This cross-sectional study recruited 2432 patients with Type 2 diabetes from Tianjin Medical University General Hospital between 2016 and 2019. Logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association between hormone levels and DR.
Results: DR was diagnosed in 953 patients (39.19%), with no significant gender difference in prevalence. Among men, DR prevalence increased with testosterone level increasing (Q4 vs. Q1: odds ratio [OR] = 1.64; 95% confidence interval [CI], 1.11-2.41) but decreased with prolactin levels increasing (Q4 vs. Q1: OR = 0.65; 95% CI, 0.44-0.96). Among women, high follicle-stimulating hormone (FSH) (Q4 vs. Q1: OR = 2.22; 95% CI, 1.40-3.52) and luteinizing hormone (LH) levels (Q4 vs. Q1: OR = 1.77; 95% CI, 1.20-2.63) were linked with increased DR prevalence. No associations were found in premenopausal women, but postmenopausal women with high prolactin level had increased DR prevalence (Q2 vs. Q1: OR = 1.56; 95% CI, 1.01-2.19). Dose-response relationships were suggested for FSH (P = 0.087) and testosterone (P = 0.088) with DR prevalence, though caution is advised due to the risk of type I error arising from multiple comparisons. Other risk factors included low body mass index (OR = 0.98), smoking (OR = 1.32), long diabetes duration (OR = 1.02), and high systolic blood pressure (OR = 1.01).
Conclusions: prolactin (negatively) and testosterone (positively) were correlated with DR risk in men. FSH and testosterone showed suggestive dose-response relationship with DR prevalence in postmenopausal women. Further research is needed for type 1 diabetes.
Translational Relevance: Sex hormones play a crucial role in DR development, affecting men and women differently.

References

  1. Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4458-63 [PMID: 20805569]
  2. Cureus. 2021 Jul 9;13(7):e16288 [PMID: 34381648]
  3. JAMA. 2006 Mar 15;295(11):1288-99 [PMID: 16537739]
  4. J Diabetes Investig. 2021 Jul;12(7):1228-1235 [PMID: 33202100]
  5. Diabetologia. 1982 Jun;22(6):412-20 [PMID: 7049799]
  6. Curr Diabetes Rev. 2017;13(2):148-160 [PMID: 27183843]
  7. Acta Diabetol. 2016 Apr;53(2):227-36 [PMID: 25959422]
  8. J Midlife Health. 2021 Apr-Jun;12(2):155-160 [PMID: 34526751]
  9. Acta Diabetol. 2015 Feb;52(1):73-80 [PMID: 24880522]
  10. J Diabetes Investig. 2019 Sep;10(5):1307-1317 [PMID: 30628186]
  11. Health Care Women Int. 2021 Jan;42(1):58-66 [PMID: 32779965]
  12. Arch Ophthalmol. 1994 Sep;112(9):1217-28 [PMID: 7619101]
  13. Lancet Diabetes Endocrinol. 2020 Apr;8(4):337-347 [PMID: 32113513]
  14. Diabetes Care. 2020 Mar;43(3):677-682 [PMID: 31949085]
  15. Ophthalmology. 2003 Sep;110(9):1677-82 [PMID: 13129861]
  16. Diabetes Care. 2002 Aug;25(8):1320-5 [PMID: 12145228]
  17. Sci Rep. 2021 Feb 26;11(1):4731 [PMID: 33637847]
  18. Eur J Endocrinol. 2010 Apr;162(4):747-54 [PMID: 20061333]
  19. J Diabetes Complications. 2022 Nov;36(11):108259 [PMID: 36150365]
  20. Diabetes Metab Res Rev. 2022 Feb;38(2):e3494 [PMID: 34514697]
  21. Ophthalmology. 2017 Apr;124(4):424-430 [PMID: 27914837]
  22. Diabetes. 2010 Dec;59(12):3192-7 [PMID: 20823101]
  23. Diabetologia. 2021 Apr;64(4):814-825 [PMID: 33452586]
  24. Ann Ophthalmol. 1993 Jun;25(6):227-30 [PMID: 8338319]
  25. Diabetologia. 2001 Feb;44(2):156-63 [PMID: 11270671]
  26. Ophthalmology. 2021 Nov;128(11):1580-1591 [PMID: 33940045]
  27. J Clin Endocrinol Metab. 2015 Oct;100(10):3778-86 [PMID: 26200237]
  28. Diabetes Care. 2012 Mar;35(3):556-64 [PMID: 22301125]
  29. Curr Eye Res. 2018 Oct;43(10):1286-1289 [PMID: 29966451]
  30. Eye (Lond). 2023 Feb;37(2):220-227 [PMID: 35501601]
  31. Transl Vis Sci Technol. 2020 Aug 17;9(9):27 [PMID: 32879783]
  32. Diabetes Metab J. 2018 Jun;42(3):179-187 [PMID: 29885111]
  33. J Diabetes Res. 2021 Jan 28;2021:5340453 [PMID: 33575359]
  34. Cardiovasc Diabetol. 2012 Oct 16;11:130 [PMID: 23066943]
  35. Wien Klin Wochenschr. 2019 May;131(Suppl 1):6-15 [PMID: 30980151]
  36. Curr Eye Res. 2018 Aug;43(8):1041-1044 [PMID: 29677452]
  37. Diabetologia. 2011 Aug;54(8):1977-84 [PMID: 21638132]
  38. Lancet. 1977 Jan 1;1(8001):45 [PMID: 63683]
  39. Biomed Environ Sci. 2004;17 Suppl:1-36 [PMID: 15807475]
  40. Diabetologia. 2007 Oct;50(10):2076-84 [PMID: 17701157]

MeSH Term

Humans
Cross-Sectional Studies
Diabetes Mellitus, Type 2
Female
Male
Middle Aged
Diabetic Retinopathy
Prevalence
Prolactin
Luteinizing Hormone
Testosterone
Risk Factors
Aged
Adult
Follicle Stimulating Hormone
Odds Ratio
China

Chemicals

Prolactin
Luteinizing Hormone
Testosterone
Follicle Stimulating Hormone

Word Cloud

Created with Highcharts 10.0.0=1DROR95%prevalencevsQ1:0womenhormonelevelstestosteroneQ4CItype2diabetesmenincreasedhighFSHriskrelationshippatientsoddsconfidenceAmonglevelincreasingprolactinpostmenopausalPPurpose:explorediabeticretinopathyMethods:cross-sectionalstudyrecruited2432TianjinMedicalUniversityGeneralHospital20162019LogisticregressionusedestimateratiosORsintervalsCIsassociationResults:diagnosed9533919%significantgenderdifferenceratio[OR]64interval[CI]11-241decreased6544-096follicle-stimulating2240-352luteinizingLH7720-263linkedassociationsfoundpremenopausalQ25601-219Dose-responserelationshipssuggested087088thoughcautionadviseddueerrorarisingmultiplecomparisonsfactorsincludedlowbodymassindex98smoking32longduration02systolicbloodpressure01Conclusions:Prolactinnegativelypositivelycorrelatedshowedsuggestivedose-responseresearchneededTranslationalRelevance:SexhormonesplaycrucialroledevelopmentaffectingdifferentlyAssociationHormoneLevelsRetinopathyPatientsTypeDiabetes:Cross-SectionalStudy

Similar Articles

Cited By

No available data.